---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-296553"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T11:07:16.776798+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023

## Summary
- Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.
- Martin expected to become CEO on July 27, 2023, per settlement with Danaher entities.
- Settlement limits Martin's responsibilities and bars involvement in Nucleic Acid Production segment until July 26, 2023.
- Carl Hull continues as Executive Chairman and interim CEO; lawsuit voluntarily dismissed.
- Christine Dolan remains COO of Biologics Safety Testing segment, reporting to Martin.

## SEC filing metadata
- accession: 0001193125-22-296553
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/d428491d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-296553
- JSON: https://secwatch.observer/filing/0001193125-22-296553.json
- Plain text: https://secwatch.observer/filing/0001193125-22-296553.txt

## Key facts
- Executive change
  William "Trey" Martin, III changed role as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..
  - Action: assume the role of
  - Role: Chief Executive Officer
  source text: its expectation that Martin will assume the role of Chief Executive Officer of the Company effective July 27, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm
- Executive change
  William "Trey" Martin, III was appointed as President of Biologics Safety Testing Segment at MARAVAI LIFESCIENCES HOLDINGS, INC..
  - Action: to serve as
  - Role: President of Biologics Safety Testing Segment
  source text: William “Trey” Martin, III to serve as President of Maravai’s Biologics Safety Testing Segment beginning December 5, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.